Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Pierre Fabre étend ses droits sur le Nerlynx de Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Pierre Fabre and ValenzaBio collaborate on anti-IGF-1R antibody for TE
Puma regains China rights to Nerlynx and amends deal with Fabre
CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Puma Biotechnology | Evaluate
Puma Biotech Expands Pierre Fabre License to Add Countries
Pierre Fabre pens oncology pact with atomic energy spinout | Fierce Biotech
Puma licences breast cancer therapy Nerlynx to Pierre Fabre in Europe
Partners of the Pierre Fabre Group: from health to beauty
Fight against cancer : our therapeutic responses | Pierre Fabre
Pierre Fabre & NERLYNX commercialisation | Nerlynx
Fight against cancer : our therapeutic responses | Pierre Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Puma Bio: A Contrarian Investment That Requires Patience (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Puma regains China rights to Nerlynx and amends deal with Fabre
Pierre Fabre engagements | NERLYNX
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Bio: Sifting Through The Q4 Earnings Report (NASDAQ:PBYI) | Seeking Alpha
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
